Breaking News: Rusfertide's Promising Journey for Polycythemia Vera Patients
Rusfertide, a potential game-changer for polycythemia vera (PV) treatment, has shown remarkable results in a recent phase 3 study, VERIFY. This study, presented at the 2025 ASH Annual Meeting, highlights the drug's ability to maintain control over hematocrit levels and reduce the need for phlebotomy, offering a ray of hope for PV patients.
But here's where it gets controversial...
The study revealed that patients who switched from a placebo to rusfertide experienced a swift and sustained drop in their hematocrit levels within just four weeks. By week 52, both groups achieved similar control over hematocrit levels, regardless of their initial treatment. For those who continued with rusfertide from the study's first part, the response rate, indicating freedom from phlebotomy, increased from 76.9% to an impressive 84.1%. And for those who made the switch from placebo, the response rate skyrocketed from 32.9% to an astonishing 77.9%.
Lead investigator Dr. Andrew Kuykendall from Moffitt Cancer Center's Department of Malignant Hematology commented, "Rusfertide demonstrated its efficacy and safety profile, meeting all primary and secondary endpoints in the VERIFY study. After 52 weeks, rusfertide was well-tolerated, and we're excited about its potential for long-term management of PV."
Key Takeaways from the VERIFY Study:
- Rusfertide maintained hematocrit control below 45% and high rates of phlebotomy ineligibility for 52 weeks in PV patients.
- Patients switching from placebo to rusfertide saw rapid and sustained hematocrit reduction, normalizing iron parameters without worsening systemic iron deficiency.
- The treatment was generally well-tolerated, with mostly mild-to-moderate adverse events, supporting its ongoing evaluation and regulatory submission.
Study Design of VERIFY:
The phase 3 VERIFY study was divided into several parts. In part 1a, patients were randomly assigned to receive either the current standard of care plus rusfertide or a placebo for 32 weeks. After this initial period, patients who received the placebo crossed over to rusfertide plus standard care (part 1b). The study continued until week 52, assessing the durability of the response. Standard care included phlebotomy with or without cytoreductive therapy. Subsequent parts of the study are ongoing to evaluate long-term safety.
Results from Part 1a:
In part 1a, rusfertide outperformed placebo across all key endpoints. Response rates more than doubled with rusfertide (76.9%) compared to placebo (32.9%). Additionally, 62.6% of patients on rusfertide achieved a hematocrit below 45%, while only 14.4% of placebo patients did (P <.0001). Rusfertide also reduced the need for phlebotomy, with a mean of 0.5 phlebotomies compared to 1.8 for placebo (P <.0001).
Patient-reported outcomes also favored rusfertide. Patients reported less fatigue and improved symptom scores, indicating an overall better quality of life.
New Findings from Part 1b:
The median time to phlebotomy was not reached for patients on rusfertide in part 1a, compared to 16 weeks for the placebo group. In part 1b, the median time to phlebotomy was not estimable in either group. Once patients switched from placebo to rusfertide, the time to first phlebotomy was similar in both groups.
Ferritin levels normalized over time with rusfertide, and there was a consistent improvement throughout the study. Placebo patients saw no change in ferritin levels in part 1a, but a consistent rise once they switched to rusfertide. Serum iron levels increased slightly in both groups, and transferrin levels decreased with rusfertide while transferrin saturation increased.
"Rusfertide effectively lowered hematocrit levels without exacerbating systemic iron deficiency," Dr. Kuykendall explained.
There was a modest improvement in mean corpuscular volume levels with rusfertide, and leukocyte counts remained stable with a slight increase. Platelet counts also improved with rusfertide.
Safety Profile of Rusfertide:
At the data cutoff, the majority of patients (86.7%) continued to receive open-label rusfertide, with discontinuations being relatively uncommon. In part 1a, only 7.5% of patients discontinued rusfertide due to adverse events or study withdrawal, compared to 4.1% in the placebo group. In part 1b, the discontinuation rate was 2.6%, with most discontinuations attributed to adverse events or lack of efficacy.
Most adverse events were mild to moderate in severity, and the rates of treatment-emergent adverse events were similar between groups in part 1b. The most common grade 3 adverse events were anemia, asthenia, and hypertension, occurring in 3 patients each.
In part 1a, injection site reactions were more common in the rusfertide group (55.9%) compared to the placebo group (32.9%). In part 1b, infusion site reactions were observed in 32.9% of patients who switched from placebo and 9.7% in the rusfertide arm.
"Interestingly, injection site reactions decreased in the rusfertide arm from week 32 to 52, suggesting a potential improvement over time," Dr. Kuykendall noted.
Future Steps for Rusfertide:
A regulatory submission is planned for rusfertide as a treatment for PV patients, with data from the VERIFY and REVIVE studies supporting its application. In the REVIVE study, the response rate with rusfertide was 60% compared to 17% for placebo.
Parts 2 and 3 of the VERIFY study will continue to assess the long-term efficacy and safety of rusfertide, providing further insights into its potential as a PV treatment option.
And this is the part most people miss...
While the results are promising, further research and real-world data are needed to fully understand the long-term benefits and potential risks of rusfertide. What are your thoughts on this potential new treatment option for PV patients? Share your insights and questions in the comments below!
